Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy
- PMID: 28685247
- DOI: 10.1007/s12016-017-8622-7
Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy
Abstract
Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated prevalence of 0.5% of the general population, characterized by the development of white macules resulting from a loss of epidermal melanocytes. The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and vitiligo (formerly non-segmental vitiligo) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses. The auto-immune/inflammatory theory is the leading hypothesis because (1) vitiligo is often associated with autoimmune diseases; (2) most vitiligo susceptibility loci identified through genome-wide association studies encode immunomodulatory proteins; and (3) prominent immune cell infiltrates are found in the perilesional margin of actively depigmenting skin. However, other studies support melanocyte intrinsic abnormalities with poor adaptation of melanocytes to stressors leading to melanocyte instability in the basal layer, and release of danger signals important for the activation of the immune system. Recent progress in the understanding of immune pathomechanisms opens interesting perspectives for innovative treatment strategies. The proof of concept in humans of targeting of the IFNγ /Th1 pathway is much awaited. The interplay between oxidative stress and altered immune responses suggests that additional strategies aiming at limiting type I interferon activation pathway as background stabilizing therapies could be an interesting approach in vitiligo. This review covers classification and clinical aspects, pathophysiology with emphasis on immunopathogenesis, and promising therapeutic approaches.
Keywords: Immunopathology; Pathophysiology; Review; Therapy; Vitiligo.
Similar articles
-
New insights into immune mechanisms of vitiligo.G Ital Dermatol Venereol. 2016 Feb;151(1):44-54. Epub 2015 Oct 29. G Ital Dermatol Venereol. 2016. PMID: 26512930 Review.
-
The enigma and challenges of vitiligo pathophysiology and treatment.Pigment Cell Melanoma Res. 2020 Nov;33(6):778-787. doi: 10.1111/pcmr.12878. Epub 2020 Apr 12. Pigment Cell Melanoma Res. 2020. PMID: 32198977 Review.
-
Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.Clin Rev Allergy Immunol. 2021 Dec;61(3):299-323. doi: 10.1007/s12016-021-08868-z. Epub 2021 Jul 20. Clin Rev Allergy Immunol. 2021. PMID: 34283349 Review.
-
Genetic and immune dysregulation in vitiligo: Insights into autoimmune mechanisms and disease pathogenesis.Autoimmun Rev. 2025 Jul 31;24(8):103841. doi: 10.1016/j.autrev.2025.103841. Epub 2025 Jun 3. Autoimmun Rev. 2025. PMID: 40466982 Review.
-
Vitiligo.Nat Rev Dis Primers. 2015 Jun 4;1:15011. doi: 10.1038/nrdp.2015.11. Nat Rev Dis Primers. 2015. PMID: 27189851 Review.
Cited by
-
Current Concepts of Vitiligo Immunopathogenesis.Biomedicines. 2022 Jul 8;10(7):1639. doi: 10.3390/biomedicines10071639. Biomedicines. 2022. PMID: 35884944 Free PMC article. Review.
-
Fatty acid-binding protein 4 circulating levels in non-segmental vitiligo.An Bras Dermatol. 2022 Jan-Feb;97(1):28-36. doi: 10.1016/j.abd.2021.04.014. Epub 2021 Nov 25. An Bras Dermatol. 2022. PMID: 34839983 Free PMC article.
-
Antimelanocyte Antibodies: A Possible Role in Patients with Vitiligo.Indian J Dermatol. 2020 Jan-Feb;65(1):33-37. doi: 10.4103/ijd.IJD_344_18. Indian J Dermatol. 2020. PMID: 32029937 Free PMC article.
-
Comorbidities Associated with Vitiligo: Results from the EpiChron Cohort.J Clin Med. 2025 Jan 11;14(2):432. doi: 10.3390/jcm14020432. J Clin Med. 2025. PMID: 39860439 Free PMC article.
-
Lymphoid Stress Surveillance Response Contributes to Vitiligo Pathogenesis.Front Immunol. 2018 Nov 20;9:2707. doi: 10.3389/fimmu.2018.02707. eCollection 2018. Front Immunol. 2018. PMID: 30515176 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical